SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001047469-20-005081
Filing Date
2020-10-02
Accepted
2020-10-02 17:17:16
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 a2242401z424b5.htm 424B5 397753
2 G178942.JPG g178942.jpg GRAPHIC 25876
  Complete submission text file 0001047469-20-005081.txt   434804
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 424B5 | Act: 33 | File No.: 333-235889 | Film No.: 201221215
SIC: 2834 Pharmaceutical Preparations